Search the Newsreel

Acquisition of Own Shares

Lakefront Biotherapeutics NV announced the repurchase of 103,970 of its own shares between August 3 and August 7, 2026, as part of a previously announced repurchase program. The shares were acquired via a discretionary mandate to an independent financial intermediary, with a total value …

Lakefront Biotherapeutics (LKFT) swings to H1 2026 profit and tightens cash outlook

Lakefront Biotherapeutics (LKFT) reported a net profit of €16.6 million for the first half of 2026, a significant turnaround from a €259.1 million net loss in H1 2025, primarily due to reduced operating losses and substantial net financial income. The company completed the acquisition …

Lakefront Biotherapeutics (ENXTAM:LKFT) Stock Reflects Profit Fragility After Revenue Reset

Shinagawa Refra (TSE:5351) Stock Faces Profit Quality Questions After One Off Gain

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Given Average Rating of "Hold" by Analysts

Lakefront Biotherapeutics (NASDAQ:LKFT) has received an average "Hold" rating from analysts, with a consensus 12-month price target of $34.33. The company recently surpassed earnings expectations, reporting an EPS of $0.04 against an anticipated loss of $0.97, and revenue of $15.47 million, significantly higher than …

Transcript : IFGL Refractories Limited, Q1 2027 Earnings Call, Aug 11, 2026

RBC Adjusts PT on Lakefront Biotherapeutics to $26 From $28, Keeps Sector Perform Rating

RBC has lowered its price target for Lakefront Biotherapeutics (LKFT) to $26 from $28, while maintaining a "Sector Perform" rating on the stock. This adjustment reflects a revised outlook from the analyst firm. The article, published on MarketScreener, notes that details are reserved for …

Shinagawa Refractories Lifts Q1 Profits and Shifts to Progressive Dividend Policy

Lakefront Biotherapeutics NV Reports Earnings Results for the Half Year Ended June 30, 2026

Lakefront Biotherapeutics NV announced its earnings results for the half year ended June 30, 2026. The company reported a significant decrease in revenue to EUR 18.6 million from EUR 140.3 million a year ago, but achieved a net income of EUR 16.6 million, a …

Lakefront Biotherapeutics H1 Net Profit From Continuing Operations EUR15.8 Mln

Lakefront Biotherapeutics H1 2026 Results: Net profit turns positive at €16.6 million

Lakefront Biotherapeutics reported a net profit of €16.6 million for H1 2026, a significant turnaround from a €259.1 million loss in H1 2025, primarily due to reduced R&D costs and positive fair value adjustments. The company completed the acquisition of Ouro Medicines, maintains a …

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Posts Earnings Results, Beats Expectations By $1.01 EPS

Lakefront Biotherapeutics H1 FY26 net sales drop 87% to EUR 18.6 million; operating loss narrows 54% to EUR 107.2 million

Lakefront Biotherapeutics reported a significant drop in H1 FY26 net sales by 87% to €18.6 million, though it swung to a net profit of €16.6 million and narrowed its operating loss by 54% to €107.2 million. The company's R&D and SG&A expenses also decreased, …

Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update

Lakefront Biotherapeutics Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval Maintain year-end 2026 cash and financial investments balance guidance of ~€2B, and …

IFGL Refractories appoints Mukesh Rawal as CEO India for three years

IFGL Refractories Reports Q1 Net Profit of 171M Rupees, Revenue Hits 5B Rupees

IFGL Refractories Elevates Veteran Executive Mukesh Rawal as India CEO

IFGL Refractories Q1 Results: Net Profit Surges 58% YoY to ₹17.06 Crore

Lakefront Biotherapeutics NV (XAMS:LKFT) Stock Forecast, Price Targets and Analysts Predictions

This article provides a stock forecast, price targets, and analyst predictions for Lakefront Biotherapeutics NV (XAMS:LKFT). It highlights the company's current market capitalization, enterprise value, PE ratio, PB ratio, and GF Score, indicating its financial health and valuation metrics. The content also offers access …

Earnings To Watch: Lakefront Biotherapeutics NV (XAMS:LKFT) Q2 2026 -- GF Value Sees 496% Upside

Lakefront Biotherapeutics NV (XAMS:LKFT) is expected to release its Q2 2026 earnings on August 10, 2026, with revenue estimates at $74.83 million and earnings at -$0.43 per share. Despite some estimate declines for 2026 and 2027, the company significantly beat previous quarter's expectations. Analysts …

Energy Fuels (TSX:EFR) Stock Faces Cash Burn As Uranium Margins Shine

IFGL Refractories Q1 Results: Earnings call scheduled for Aug 11

Energy Fuels Inc earnings missed by $0.10, revenue fell short of estimates

Earnings Flash (UUUU) Energy Fuels Inc. Reports Q2 Revenue $25.1M, vs. FactSet Est of $30.8M

Energy Fuels Inc. Provides Earnings Guidance for the Full Year 2026

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Sets New 52-Week Low - Here's What Happened

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) hit a new 52-week low of $26.41 before closing at $26.67 on Monday. Despite beating quarterly EPS expectations with $0.25 versus an estimated loss of $1.27, the company's revenue of $8.75 million fell short of the $11.26 million …

Lefroy Exploration flags Mt Martin gold growth potential with high-grade hits

Eneco Refresh (ASX: ERG) Share Price Falls 16% on Tuesday – Here’s Why

Lakefront Biotherapeutics American Depositary Shares (LKFT) Expected to Post Quarterly Earnings on Monday

Eneco Refresh (ASX:ERG): The ASX's Lone Bottled-Water Play, Squeezed on Costs

Eneco Refresh Posts $17.73M Full-Year Revenue as Q4 Sales Rise 7% to $4.22M

Lefroy Exploration Shareholders Back Capital Placement and Director Share Issues

Eneco Refresh Lifts FY2026 Revenue Amid Resin Price Volatility